CDK4/6 inhibition in high-risk early breast cancer

CDK4/6 inhibitors (plus endocrine therapy) have shown to improve overall survival of patients with ER-positive/HER2-negative breast cancer who progressed on endocrine therapy [1-3]. First results of the monarchE trial showed abemaciclib to improve disease-free survival in patients with early, high-risk, ER-positive/HER2-negative breast cancer [4]. In contrast, in the PALLAS trial, palbociclib did not [5]. In the open-label, phase 3 monarchE trial, 5,637 patients with early, high-risk ER-positive/HER2-negative breast cancer were 1:1 randomised to abemaciclib (150 mg twice daily for 2 years) plus endocrine therapy or endocrine therapy alone. Abemaciclib plus endocrine therapy demonstrated a significant improvement in invasive disease-free survival (iDFS) versus endocrine therapy alone (HR 0.747; P=0.0096), corresponding to a 25.3% reduction in the risk of an IDFS event (see Figure). The 2-year iDFS rates were 92.2% versus 88.7%, respectively. Consistent ben...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 November, 202024 November, 2020